The three-year program, funded by Takeda, will be led by Nigel Bunnett, deputy director at MIPS and Daniel Poole, PhD, also from MIPS. The program will aim to examine and better understand the causes of disorders of gastrointestinal function and sensation.
“A major thrust of the work will be to make use of our expertise in nano-medicine to deliver drugs to the source of disease within the body,” said Professor Bunnett to GEN News.
More articles on gastroenterology:
147 gastroenterologist leadership moves & honors in 2014
23 GI-driven ASCs & facilities opened or announced in 2014
Physicians vs. computers: Who creates better patient reports?
